Abstract
Some physiopathological processes involved in the genesis of diseases could suggest the necessity of designing bioligands or prototypes that aggregate, in only one molecule, dual pharmacodynamical properties, becoming able to be recognized by two elected bioreceptors. This approach can have distinct aspects and, when a novel ligand or a prototype acts in two elected targets belonging to the same biochemical pathway, e.g. arachidonic acid cascade, it receives the denomination of dual or mix agent. On the other hand, if these two targets belong to distinct biochemical routes and both are related to the same disease, we can characterize the agents able to modulate it as symbiotic ligands or prototypes. In the present work, we provide some examples and applications of the molecular hybridization concept for the structural design of new symbiotic ligands and prototypes, especially those applied in the treatment of chronic-degenerative disorders.
Keywords: Symbiotic drugs, molecular hybridization, multifactorial diseases, therapeutic innovation, drug design, dual compounds
Current Drug Therapy
Title: New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Volume: 3 Issue: 1
Author(s): Carlos Alberto Manssour Fraga and Eliezer J. Barreiro
Affiliation:
Keywords: Symbiotic drugs, molecular hybridization, multifactorial diseases, therapeutic innovation, drug design, dual compounds
Abstract: Some physiopathological processes involved in the genesis of diseases could suggest the necessity of designing bioligands or prototypes that aggregate, in only one molecule, dual pharmacodynamical properties, becoming able to be recognized by two elected bioreceptors. This approach can have distinct aspects and, when a novel ligand or a prototype acts in two elected targets belonging to the same biochemical pathway, e.g. arachidonic acid cascade, it receives the denomination of dual or mix agent. On the other hand, if these two targets belong to distinct biochemical routes and both are related to the same disease, we can characterize the agents able to modulate it as symbiotic ligands or prototypes. In the present work, we provide some examples and applications of the molecular hybridization concept for the structural design of new symbiotic ligands and prototypes, especially those applied in the treatment of chronic-degenerative disorders.
Export Options
About this article
Cite this article as:
Manssour Fraga Alberto Carlos and Barreiro J. Eliezer, New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs, Current Drug Therapy 2008; 3 (1) . https://dx.doi.org/10.2174/157488508783331225
DOI https://dx.doi.org/10.2174/157488508783331225 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Scopolamine and Depression: A Role for Muscarinic Antagonism?
CNS & Neurological Disorders - Drug Targets Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Diverse Thiophenes as Scaffolds in Anti-cancer Drug Development: A Concise Review
Mini-Reviews in Medicinal Chemistry Triterpenes from Gloeophyllum odoratum as Potential Leads Towards Potent Thrombin Inhibitors
Letters in Drug Design & Discovery Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Exogenous Factors from Venomous and Hematophagous Animals in Drugs and Diagnostic Developments for Cardiovascular and Neurovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
Current Drug Safety The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Advances in the Pharmacological and Non-pharmacological Management of Non-motor Symptoms in Parkinson’s Disease: An Update Since 2017
Current Neuropharmacology